一项关于在超声内镜辅助下使用聚桂醇消融胰腺囊性肿瘤安全性和有效性的前瞻性研究
2015年4月至2016年5月纳入120例胰腺囊性肿瘤患者行超声内镜,其中29例接受超声内镜引导下聚桂醇消融并前瞻性随访。29例中7例接受第二次消融,共36次治疗;平均肿瘤直径由术前28.6±14.5 mm降至术后13.4±10.5 mm。完全随访9个月(范围3-15个月)的29次治疗中,完全缓解11例、部分缓解9例,消退率37.9%(11/29)。作者认为该消融安全有效,不良事件率在头/钩突部似乎更高,但消退率相似,需更大样本和更长随访的进一步研究。
要点
- 超声内镜引导下聚桂醇消融胰腺囊性肿瘤共36次治疗,平均直径由28.6±14.5 mm降至13.4±10.5 mm。
- 29次治疗完全随访9个月(范围3-15个月),完全缓解11例、部分缓解9例,消退率37.9%(11/29)。
- 消退率头/钩突部36.4%(8/22)与体/尾部42.9%(3/7)相比P>.05。
核心结论
- 作者认为超声内镜引导下聚桂醇消融胰腺囊性肿瘤安全且有效。
- 不良事件率在头/钩突部似乎高于体/尾部,但两者消退率相似。
- 作者提出需更大样本和更长随访的进一步研究。
研究设计与样本
- 前瞻性研究,2015年4月至2016年5月纳入120例胰腺囊性肿瘤患者行超声内镜,其中29例接受超声内镜引导下聚桂醇消融。
- 29例中7例接受第二次消融,共36次治疗。
- 消融后3个月和6个月行增强CT或磁共振随访,通过囊肿体积变化判定消融有效性。
主要发现
- 平均肿瘤直径术前28.6±14.5 mm,术后13.4±10.5 mm。
- 轻度胰腺炎2例、中度发热1例,均发生于位于头/钩突部的囊肿。
- 29次治疗完全随访9个月(范围3-15个月),完全缓解11例、部分缓解9例。
- 消退率37.9%(11/29),头/钩突部36.4%(8/22)vs 体/尾部42.9%(3/7),P>.05。
局限性
- 作者提出需更大样本和更长随访的进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: With the development of imaging techniques, the detection rate of pancreatic cystic neoplasms (PCNs) has increased. The surgical morbidity and mortality rates of PCNs are quite high. This study is intended to evaluate the safety and effectiveness of a minimally invasive treatment, EUS-guided PCN ablation with lauromacrogol. METHODS: From April 2015 to May 2016, 120 patients with PCNs were enrolled to undergo EUS. We prospectively studied 29 of the 120 patients who underwent EUS-guided ablation with lauromacrogol. The follow-up contrast-enhanced CT or magnetic resonance image was conducted at 3 months and then 6 months after ablation. We determined the effectiveness of ablation by the changes in the volume of the cysts. RESULTS: Twenty-nine patients were enrolled in the study, and 7 of them underwent a second ablation; therefore, there were 36 treatments. The mean tumor diameter was 28.6 ± 14.5 mm preoperation, whereas the diameter postoperation was 13.4 ± 10.5 mm. Mild pancreatitis occurred in 2 patients and moderate fever in 1; they occurred in the cysts located in the head/uncinate. Among the 29 treatments with complete follow-up of 9 months (range, 3-15), 11 had complete response and 9 had partial response. The resolution rate was 37.9% (11/29) with 36.4% (8/22) in the cysts of the head/uncinate and 42.9% (3/7) in the body/tail (P > .05). CONCLUSIONS: EUS-guided PCN ablation with lauromacrogol is safe and efficient. Adverse event rates seem to be higher in the head/uncinate than in the body/tail, but their resolution rates are similar. Further studies involving larger populations and longer follow-ups are warranted.
引用
- Linghu E, Du C, Chai N, et al. A prospective study on the safety and effectiveness of using lauromacrogol for ablation of pancreatic cystic neoplasms with the aid of EUS. Gastrointest Endosc. 2017. PMID: 28365355. doi:10.1016/j.gie.2017.03.1525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。